Eculizumab biosimilar - Amgen

Drug Profile

Eculizumab biosimilar - Amgen

Alternative Names: ABP 959

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Paroxysmal nocturnal haemoglobinuria
  • Phase I Haemolytic uraemic syndrome

Most Recent Events

  • 04 Sep 2017 Phase-III clinical trials in Paroxysmal nocturnal haemoglobinuria in Spain (IV) before September 2017(EudraCT2017-001418-27)
  • 25 Mar 2017 Amgen completes a phase I trial in Paroxysmal nocturnal haemoglobinuria and Haemolytic uraemic syndrome (In volunteers) in Australia (IV) (ACTRN12616000509460)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top